|
Match
|
Document |
Document Title |
|
|
7589075 |
Use of an adenosine A3 receptor agonist for inhibition of viral replication
The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In...
|
|
|
7579354 |
Adenosine receptor antagonists and methods of making and using the same
The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful...
|
|
|
7560450 |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
The present invention relates to substituted xanthines of general formula
the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable...
|
|
|
7495003 |
8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
The application relates to new substituted xanthines of general formula
wherein R 1 and R 2 are defined as in claims 1 to 11 , the tautomers, the enantiomers, the diastereomers, the...
|
|
|
7495002 |
3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
The present invention relates to new substituted xanthines of general formula
wherein R 1 , R 2 and X are defined as in the claims, the tautomers, the enantiomers, the diastereomers, the...
|
|
|
7495004 |
Purine derivatives as liver X receptor agonists
The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cardiovascular disease and atherosclerosis, novel compounds of formula (I) for...
|
|
|
7482337 |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
Disclosed are substituted xanthines of general formula
wherein R 1 to R 4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts...
|
|
|
7423041 |
A1 adenosine receptor antagonists
Compounds of the general formula (I) are described:
wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also...
|
|
|
7312223 |
Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure
derivatives, and formulations thereof, and processes for...
|
|
|
7098217 |
3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are provided
wherein R 1 , R 2 , R 3 and R 4 are herein defined for use as CRF receptor ligands in the treatment of disorders...
|
|
|
7053096 |
Compounds having selective hydrolytic potentials
Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in...
|
|
|
6878715 |
Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations...
|
|
|
6780865 |
Compounds having selective hydrolytic potentials
Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in...
|
|
|
6734187 |
Purine derivatives and medicaments comprising the same as active ingredient
Purine derivatives represented by the following formula and salts thereof: wherein R 1 represents a C 1 -C 4 alkyl group or difluoromethyl group; R 2 represents tetrahydrofuranyl group, a C 1...
|
|
|
6649600 |
Adenosine receptor antagonists and methods of making and using the same
The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be usefull...
|
|
|
6638938 |
Method for preventing tissue injury from hypoxia
There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular...
|
|
|
6608069 |
Phenyl xanthine derivatives
The present invention relates to novel compounds of formula (I): wherein Z represents a 5 or 6 membered cycloalkyl, aryl, substituted cycloalkyl, or substituted aryl, said cycloalkyl, aryl,...
|
|
|
6605600 |
Adenosine receptor antagonists and methods of making and using the same
The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful...
|
|
|
6558660 |
Method for regulating IL-10 with IL-9, and applications thereof
The invention involves the recognition of IL-9 as a molecule involved in induction of IL-10. Administration of IL-9 leads to protection against conditions where IL-10 production is warranted, such...
|
|
|
6423719 |
Method for treating benign prostate hyperplasia
A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: is described herein....
|
|
|
6350752 |
Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo...
|
|
|
6319894 |
Complexes and combinations of fetuin with therapeutic agents
There is disclosed a complex and a combination of the glycosylated polypeptide fetuin and a therapeutically active small molecule compound having a net positive charge at physiological pH. The...
|
|
|
6313131 |
Method of kidney treatment
A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: ##STR1## is described...
|
|
|
6294541 |
Purine derivatives having phosphodiesterase IV inhibition activity
A compound of the formula: ##STR1## wherein R 3 represent a C 1 -8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO 2 H, NOH, NOCONH 2 , or...
|
|
|
6187780 |
Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
Asymmetrically substituted xanthine derivatives having adenosine A 1 antagonistic activity. These are useful as pharmaceuticals. Exemplary are: (a)...
|
|
|
6103730 |
Amine substituted compounds
Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula: CORE MOIETY--(R) j In these...
|
|
|
6100271 |
Therapeutic compounds containing xanthinyl
Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R) j wherein j is an integer from one to three. The core moiety is...
|
|
|
6043250 |
Methods for using therapeutic compounds containing xanthinyl
Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R) j wherein j is an integer from one to three. The core moiety is...
|
|
|
5965555 |
Xanthine compounds having terminally animated alkynol side chains
Compounds of the formula I, ##STR1## in which one of the radicals R 1 and R 3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a...
|
|
|
5958933 |
Neurologically active compounds and compounds with multiple activities
A method for treating a mammal having a damaged central nervous system, as the result of trauma or disease, for reestablishing previously destroyed neurological functions in a traumatized or...
|
|
|
5929081 |
Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and VEGF
There is disclosed a method for: (1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's...
|
|
|
5889011 |
Substituted amino alkyl compounds
Compounds and pharmaceutical compositions thereof comprise the formula: (R)j- (core moiety), including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof,...
|
|
|
5861405 |
S-substituted 1,3,7-trialkyl-xanthine derivatives
The present invention provides 8-substituted 1,3,7-trialkylxanthines useful as A 2 -selective adenosine receptor antagonists and compositions comprising such compounds. Examples of the...
|
|
|
5861396 |
Purin-6-one derivatives
Purin-6-one derivatives are prepared by acylating appropriately substituted imidazole carboxamides and then cyclizing to give the purines. The purin-6-one derivatives are suitable as active...
|
|
|
5807861 |
Amine substituted xanthinyl compounds
A method for treating a disease caused by an undesirable cell response mediated by a proliferative intracellular signaling pathway is provided wherein an effective amount of a compound is...
|
|
|
5801181 |
Amino alcohol substituted cyclic compounds
Therapeutic compounds have the formula: (X)j--(core moiety), J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture,...
|
|
|
5770595 |
Oxime substituted therapeutic compounds
Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula: CORE MOIETY--(R) j including...
|
|
|
5756511 |
Method for treating symptoms of a neurodegenerative condition
A method for treating symptoms of Alzheimer's Disease by administering an effective amount of a compound, racemate, isolated R or S enantionmer, solvate, hydrate or salt having the formula: ...
|
|
|
5670507 |
Method for reversing multiple drug resistant phenotype
There is disclosed a method for reversing the multiple drug resistant (MDR) phenotype in tumors insensitive to hydrophobic chemotherapeutic drugs due to over expression of mdr-1, comprising...
|
|
|
5514694 |
Peptidyl ketoamides
A novel class of peptide α-ketoamides useful for selectively inhibiting serine proteases, selectively inhibiting cysteine proteases, generally inhibiting all serine proteases, and generally...
|
|
|
5470858 |
Derivatives of (hetero)aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them
A compound represented by the following formula I: (HET)Ar--X--CH 2 --Y--CH 2 --O--R (I) wherein: (HET)Ar represents a bicyclic hetero aryl nucleus which is unsubstituted or...
|
|
|
5470579 |
Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation
A method of treating skin or hair for promoting pigmentation wherein a xanthine component, in an amount effective to promote pigmentation, is incorporated in liposomes or hydrated lipidic lamellar...
|
|
|
5354756 |
Olefin-substituted long chain xanthine compounds
There is disclosed compounds and pharmaceutical compositions having a xanthine core and one or two hydrocarbon side chains bonded to a ring nitrogen atom, wherein the hydrocarbon side chains are...
|
|
|
5340813 |
Substituted aminoalkyl xanthine compounds
Compounds of the formula ##STR1## wherein each of one or two R is independently ##STR2## wherein n is an integer from 4 to 18, each R 1 ' and R 2 ' is independently H, alkyl (1-4C) or alkenyl...
|
|
|
5296463 |
Compositions and methods for improving cold tolerance in animals and humans
The invention disclosed is a composition for improving cold tolerance in animals and humans, comprising an adenosine receptor antagonist or an adenosine de-activator. Preferably, a nutritional...
|
|
|
5061709 |
Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition
A method is described in which the feed utilization by livestock is improved by the incorporation in the feed or drinking water of the said livestock of certain compounds, with resultant increase...
|
|
|
4299832 |
Substituted theophylline compounds
The substituted theophyllines of the formula: ##STR1## (wherein R 1 , R 2 and R 3 , which may be the same or different, each represent alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon...
|
|
|
4263301 |
β-Phenyl-β-hydroxyethylaminoalkyltheophyllines as inhibitors of biosynthesis of triglycerides
Biosynthesis of triglycerides in swine is inhibited by certain β-phenyl-β-hydroxyethylaminoalkyltheophyllines.
|
|
|
4233303 |
Xanthine derivatives
Compounds of the formula ##STR1## or physiologically acceptable salts thereof in which formula R 1 is methyl, ethyl or n-propyl, R 2 is methyl or n-propyl and R 3 is ##STR2## methods for the...
|
|
|
4144340 |
Basic substituted xanthine derivatives
There are prepared compounds corresponding to the general formula T -- Alk -- NH -- CH 2 -- CH(OH) -- CH 2 -- O -- Ar I in which T represents a theophyllinyl-(7) or theobrominyl-(1) radical,...
|